Skip to main content
$0.056 -0.002 (-3.45%)

High

$0.06

Low

$0.06

Trades

69

Turnover

$115,211

Volume

1,984,515
30 June 2023 at 3:59pm
If you were already registered, log in here.

Second Drug Program Progressing Towards Human Trials

StockBot

416,823 posts

PYC released this announcement to the ASX on 8 June 2021, 9:51. The announcement is marked as price sensitive, and is 6 page(s) in length and 389.99kb in size.

You can view all announcements from PYC and see how they appear on a price chart on the announcements page.

At the date of this announcement, PYC was 0.003% short sold according to ASIC data. It was ranked the 619th most shorted stock on the ASX. It is now ranked as the 319th most shorted stock on the ASX with 0.553% of total shares short sold as of the latest reported data (16 November 2026).

Other Recent Announcements from PYC
FIRST PATIENT DOSED IN EYE DISEASE CLINICAL TRIAL 30 June 2023, 8:17
Change of Director's Interest Notice 28 June 2023, 16:46
PYC Investor Update Presentation 16 June 2023, 8:32
Second Drug Program Progressing Towards Human Trials 8 June 2021, 9:51
Trading Halt 7 June 2021, 9:31
Evercore ISI GenomeRx Emerging Therapeutic Company Day 26 May 2021, 8:22
SECOND DRUG PROGRAM - EFFICACY DATA IN PATIENT CELL MODELS 18 May 2021, 8:23
If you were already registered, log in here.

If you were already registered, log in here.

If you were already registered, log in here.